Treatment of tuberculosis is long (≥6 months) and requires a combination of drugs. Scientists have been trying to develop more effective drug combinations although this is not straightforward.
Deciding on the best combination and amount of drugs for tuberculosis treatment when they are given in combination remains challenging. This project aims to investigate biomarkers for phenotypic variants of tuberculosis to apply them for the characterization and quantification of detailed antimicrobial responses for drug combinations. This can ultimately aid the optimization of anti-tubercular treatment.